ARCT
Price
$14.94
Change
-$0.01 (-0.07%)
Updated
Jul 25 closing price
Capitalization
405.18M
15 days until earnings call
MRNA
Price
$34.15
Change
+$0.14 (+0.41%)
Updated
Jul 25 closing price
Capitalization
13.21B
5 days until earnings call
Interact to see
Advertisement

ARCT vs MRNA

Header iconARCT vs MRNA Comparison
Open Charts ARCT vs MRNABanner chart's image
Arcturus Therapeutics Holdings
Price$14.94
Change-$0.01 (-0.07%)
Volume$326.86K
Capitalization405.18M
Moderna
Price$34.15
Change+$0.14 (+0.41%)
Volume$5.37M
Capitalization13.21B
ARCT vs MRNA Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. MRNA commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and MRNA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (ARCT: $14.94 vs. MRNA: $34.15)
Brand notoriety: ARCT: Not notable vs. MRNA: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 73% vs. MRNA: 53%
Market capitalization -- ARCT: $405.18M vs. MRNA: $13.21B
ARCT [@Biotechnology] is valued at $405.18M. MRNA’s [@Biotechnology] market capitalization is $13.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • MRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, MRNA is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while MRNA’s TA Score has 6 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 4 bearish.
  • MRNA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MRNA is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а +10.67% price change this week, while MRNA (@Biotechnology) price change was +9.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

ARCT is expected to report earnings on Aug 11, 2025.

MRNA is expected to report earnings on Aug 01, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($13.2B) has a higher market cap than ARCT($405M). ARCT YTD gains are higher at: -11.962 vs. MRNA (-17.869). ARCT has higher annual earnings (EBITDA): -63.92M vs. MRNA (-3.2B). MRNA has more cash in the bank: 5.98B vs. ARCT (217M). ARCT has less debt than MRNA: ARCT (42.7M) vs MRNA (745M). MRNA has higher revenues than ARCT: MRNA (3.14B) vs ARCT (131M).
ARCTMRNAARCT / MRNA
Capitalization405M13.2B3%
EBITDA-63.92M-3.2B2%
Gain YTD-11.962-17.86967%
P/E RatioN/AN/A-
Revenue131M3.14B4%
Total Cash217M5.98B4%
Total Debt42.7M745M6%
FUNDAMENTALS RATINGS
ARCT vs MRNA: Fundamental Ratings
ARCT
MRNA
OUTLOOK RATING
1..100
6633
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
5851
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
47n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (45) in the Pharmaceuticals Major industry is in the same range as MRNA (60) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MRNA’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as MRNA (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MRNA’s over the last 12 months.

ARCT's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as MRNA (96) in the Biotechnology industry. This means that ARCT’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's Price Growth Rating (51) in the Biotechnology industry is in the same range as ARCT (58) in the Pharmaceuticals Major industry. This means that MRNA’s stock grew similarly to ARCT’s over the last 12 months.

MRNA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that MRNA’s stock grew significantly faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTMRNA
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
77%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
76%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 7 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
OILD12.340.15
+1.23%
MicroSectorsTM Ol&Gs E&P -3X Inv Lg ETNs
REGL84.250.70
+0.84%
ProShares S&P MidCap 400 Dividend Arst
UWM40.470.26
+0.65%
ProShares Ultra Russell2000
JFLI50.030.09
+0.19%
JPMorgan Flexible Income ETF
GHYB45.32N/A
+0.01%
Goldman Sachs Access Hi Yld Corp Bd ETF

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with RXRX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-0.07%
RXRX - ARCT
52%
Loosely correlated
+3.67%
TRDA - ARCT
52%
Loosely correlated
+2.35%
RGNX - ARCT
51%
Loosely correlated
-1.86%
MRNA - ARCT
51%
Loosely correlated
+0.41%
HLVX - ARCT
51%
Loosely correlated
+0.47%
More

MRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with ARCT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNA
1D Price
Change %
MRNA100%
+0.41%
ARCT - MRNA
51%
Loosely correlated
-0.07%
BNTX - MRNA
50%
Loosely correlated
+0.65%
NVAX - MRNA
46%
Loosely correlated
-2.23%
CRSP - MRNA
46%
Loosely correlated
-1.97%
ALLO - MRNA
45%
Loosely correlated
-0.66%
More